Evidence map›Paper›PMID 38076651›Full record

ReviewBioactive materials2024

Decellularized extracellular matrix materials for treatment of ischemic cardiomyopathy.

Wei Liu, Xiangmei Zhang, Xiaokai Jiang, Binyao Dai, Liwen Zhang, Yang Zhu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 35 citations in OpenAlex.

  1. Decellularized cardiac ECM: A tissue-specific bioactive platform for drug release and cell delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wei LiuCenter for Medical Device Evaluation, National Medical Products Administration, Beijing, 100037, China.
Xiangmei ZhangGreater Bay Area Center for Medical Device Evaluation and Inspection, National Medical Products Administration, Shenzhen, 518045, China.
Xiaokai JiangMOE Key Laboratory of Macromolecular Synthesis and Functionalization Department of Polymer Science and Engineering, Hangzhou, 310027, China.
Binyao DaiMOE Key Laboratory of Macromolecular Synthesis and Functionalization Department of Polymer Science and Engineering, Hangzhou, 310027, China.
Liwen ZhangMOE Key Laboratory of Macromolecular Synthesis and Functionalization Department of Polymer Science and Engineering, Hangzhou, 310027, China.
Yang ZhuState Key Laboratory of Transvascular Lmplantation Devices, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027, China.
Zhejiang University · CNNational Medical Products Administration · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic cardiomyopathy (ICM) affect millions of patients globally. Decellularized extracellular matrix materials (dECM) have components, microstructure and mechanical properties similar to healthy cardiac tissues, and can be manufactured into various forms of implantable biomaterials including injectable hydrogels or epicardial patches, which have been extensively reported to attenuate pathological left ventricular remodeling and maintain heart function. Recently, dECM medical devices for ICM treatment have been approved for clinical use or studied in clinical trials, exhibiting considerable translation potential. Cells, growth factors and other bioactive agents have been incorporated with different dECM materials to improve the therapeutic outcomes. In addition, more detailed aspects of the biological effects and mechanisms of dECM treatment are being revealed. This review summarized recent advances in dECM materials from variable sources for cardiac repair, including extraction of extracellular matrix, cell integration, smart manufacturing of injectable hydrogels and cardiac patch materials, and their therapeutic applications. Besides, this review provides an outlook on the cutting-edge development directions in the field.

Indexed as

Decellularized extracellular matrixdECM patchesInjectable dECMIschemic cardiomyopathyMyocardial infarction

Identifiers

PMID38076651
PMCPMC10697850
OpenAlexW4389145750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.